Dunhill Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dunhill Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$697	Hold	12	–	–	﹤0.01%	1074
2026 Q1	$688	Buy	12 +8	+200%	+$466	﹤0.01%	1050
2025 Q4	$249	Buy	+4	New	+$218	﹤0.01%	1054

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dunhill Financial's BMRN Position: Q2 2026 in Review

Dunhill Financial held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 12 shares worth $697. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

Dunhill Financial first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Dunhill Financial held 12 shares of BioMarin Pharmaceuticals worth $697 as of Q2 2026.
Dunhill Financial left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1074 holding.
Dunhill Financial first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.